Stay updated on CABozantinib in NSCLC MET Clinical Trial

Sign up to get notified when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CABozantinib in NSCLC MET Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A site-wide NIH notice about terminology changes appears above the ClinicalTrials.gov page.
    Difference
    1%
    Check dated 2026-10-25T06:26:36.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changes from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T04:58:11.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The site footer revision identifier changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T08:24:07.000Z thumbnail image
  4. Check
    36 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of the study record content. Access to the study details is blocked and the expected content is not visible.
    Difference
    19%
    Check dated 2026-09-20T03:22:59.000Z thumbnail image
  5. Check
    50 days ago
    Change Detected
    Summary
    No additions or deletions were provided in the site changes data, so there is no update to report for this page.
    Difference
    0.0%
    Check dated 2026-09-05T23:58:24.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    The revision number changes from v3.6.5 to v3.6.6, indicating a small update to the page. This update appears to affect backend or formatting aspects rather than the study content.
    Difference
    0.0%
    Check dated 2026-08-29T23:45:15.000Z thumbnail image

Stay in the know with updates to CABozantinib in NSCLC MET Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.